Nonprofit Chronicles

Journalism about foundations, nonprofits and their impact

Pastor James Lindberg was unmoored by his first trip on psilocybin. “I’m a pretty normal middle aged white guy who found myself involved in things that were a bit larger than I intended them to be,” says Lindberg, who leads a Lutheran church in an Omaha suburb. He questioned his place in the church but, …

Continue reading

Civil rights. Feminism. Gay rights. Environmentalism. Meditation. Yoga. Natural childbirth. Much of the politics and culture of the 1960s has been absorbed into mainstream America. Not psychedelic drugs — not yet, anyway. That will soon change if David Bronner, the CEO of family-owned soap-maker Dr. Bronner’s, has his way. “Psychedelic medicine is the last and arguably the …

Continue reading

MDMA, the man-made drug often called ecstasy or molly, has a colorful history. It was patented in 1914 by the German drug company Merck, and set aside for decades. The US Army studied it during the Cold War, perhaps seeking a chemical weapon or interrogation tool. Alexander “Sasha” Shulgin, an iconoclastic chemist, rediscovered MDMA during …

Continue reading

This is a strange and deeply disturbing time. I’d like to be writing more about racial justice and Covid-19 and, in an indirect way, I did just this morning, at Medium. My story looks at two progressive, criminal-justice ballot initiatives that are all but certain to be on the November ballot in the state of …

Continue reading

Philanthropic dollars helped to create today’s psychedelic renaissance by funding medical research into the therapeutic benefits of psilocybin and LSD. The research has generated a great deal of excitement, as I reported last year in the Chronicle of Philanthropy and in Medium. Now, startup companies want to bring psychedelic medicines to market. That’s the topic …

Continue reading

This is a remarkable moment for psychedelics. Elite universities, including Johns Hopkins and Imperial College in London, have opened centers to research the medical benefits of such drugs as psilocybin, a hallucinogen found in certain mushrooms. The nonprofit Multidisciplinary Association for Psychedelic Research (MAPS) is recruiting people suffering from PTSD to participate in FDA-approved clinical trials using MDMA, better known as …

Continue reading